Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus melphalan conditioning before autologous stem cell transplantation in multiple myeloma
ChiCTR2400086849Phase 4Not yet recruiting
- Sponsor
- Meishan City People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor and melphalan in multiple myeloma (MM), sponsored by Meishan City People's Hospital. Primary endpoint: 3-year progression-free survival rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
selinexormelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400086849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086849.